To order EarlyCDT-Lung select the geographic region of your choice by clicking on the relevant button above
If you represent a medical laboratory or a medical diagnostics distributor and you are interested in becoming a distributor of EarlyCDT-Lung, please complete the form or contact us at email@example.com or +44 (0)115 8231869.
Physicians in USA can order EarlyCDT-Lung here.
The following distributors are currently offering the EarlyCDT–Lung test in Asia
For any enquiries regarding the following information, please email firstname.lastname@example.org
AceCGT Diagnostic Limited is a leading clinical diagnostic laboratory specializing in molecular diagnosis and early cancer detection. Please visit: http://www.acecgtdiagnostic.com/LungCDT/index.html for more information, or telephone +(852) 3979 3200.
The EarlyCDT–Lung test can be ordered by physicians or by patients from our accredited distributors in the UK
Please note that EarlyCDT-Lung is only available privately, not through the National Health Service (NHS). Patients will be required to pay for the test.
The EarlyCDT-Lung test needs to be provided under medical supervision. Patients should discuss EarlyCDT-Lung test with their family doctor or Specialist / Consultant who may order the test via The Doctors Laboratory.
Patients can also have EarlyCDT-Lung test via the LungCheck service provided by Lung Health UK. This service offers patients the required medical expertise and follow up needed. LungHealth UK is regulated by the Care Quality Commission.
To get the LungCheck service visit https://www.lunghealthuk.com/screening-services/lung-cancer-diagnosis or call 0800 085 0228.
Physicians can order EarlyCDT-Lung test from The Doctors Laboratory (TDL) which is the largest independent provider of diagnostic pathology services in the UK. TDL’s laboratories are CPA accredited in all disciplines. Please visit http://www.tdlpathology.com/ for more information about TDL.
Physicians, please contact TDL (http://www.tdlpathology.com/) on 0207 307 7343 or by email to earlyCDTLung@tdlpathology.com for information about taking and sending samples for EarlyCDT-Lung. TDL will provide you with postal packs or advise on local sample taking, or courier collection arrangements, as needed. Please ensure that your letter of referral, or your completed request form, is enclosed with the sample, confirming your details.
For information, or to order pathology packs, please telephone 0207 307 7343 or email earlyCDTLung@tdlpathology.com.
The following Consultants, available for private referrals, know specifically about EarlyCDT-Lung and are familiar with recommended follow-up procedures. Please feel free to use other Consultants as you see fit:
If you are a Consultant and would like to be included in this list, or for more information, then please contact email@example.com.
The following distributors are currently providing access to the EarlyCDT–Lung test in Europe and the Middle East
Physicians and Patients should contact distributors directly.
5230 Odense M
Tel: +45 40 35 05 50
Tarvand Sina Headquarters
Address:Unit.1, first floor, Matin administrative buildings, Sarlat alley,Tayeb st, Isfahan, Iran
Zip code: 81367-33463
E-mail : firstname.lastname@example.org
Best Med Opinion Ltd is a leading provider of second opinions, clinical services and advanced medical diagnostics in Israel and several other countries, working with insurance companies, large organizations and private patients. Best Med Opinion Ltd. has developed a network of specialty providers in the U.S. and other countries to assist physicians and patients in ensuring all clinical options are known and explored before a particular course of treatment is selected.
Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).
These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.
None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.
By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.